Clayton J. Agler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clayton J. Agler has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Sandra L. Starnes
2 shared publications- Antonio Nenna
Unit of Cardiac Surgery, Azienda Ospedaliera Maggiore della Carità, 28100 Novara, Italy
1 shared publication - Arnaldo Dimagli
Department of Surgery, Columbia University, New York, NY 10027, USA
1 shared publication - Asishana Avo Osho
Massachusetts General Hospital, Harvard Medical School
1 shared publication Catherine G. Pratt
1 shared publication- Cristiano Spadaccio
Division of Cardiac Surgery, University of Cincinnati College of Medicine , Cincinnati, Ohio
1 shared publication
Latest Publications
- Open Access
- 30 May 2026
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
The Current State of Itinerant Surgery: A Survey of Thoracic Surgeons
- 30 May 2026
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
Open AccessThe Current State of Itinerant Surgery: A Survey of Thoracic Surgeons
- Open Access
- 7 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4049
Exploring Use-Rates of and Scientific Evidence on Sutureless Devices in Aortic Valve Replacement: A Bibliographic Meta-Analysis and Clinical Considerations
Sutureless aortic valve replacement (SuAVR) has emerged as a potential alternative to conventional surgical aortic valve replacement (SAVR), particularly in minimally invasive settings. However, its global adoption remains limited, with a notable concentration of use and scientific production in select European countries. This bibliographic meta-analysis systematically reviewed 538 studies to assess the evidence landscape surrounding SuAVR, highlighting a predominance of observational data, sparse randomized controlled trials (1.3%), and significant geographical imbalances in research output. Europe accounted for 80% of publications, while North America contributed less than 10%. Key structural factors—including reimbursement policies, earlier regulatory approvals, and population characteristics—appear to influence SuAVR adoption. Despite procedural advantages such as reduced cross-clamp times, concerns over cost, pacemaker implantation rates, and uncertain long-term durability persist. Importantly, SuAVR may offer its greatest clinical value by facilitating minimally invasive surgery, a niche still underutilized worldwide. The limited randomized data and industrial focus on transcatheter approaches have further hindered widespread acceptance. Our findings underscore the need for high-quality comparative trials and standardized guidelines to define the role of SuAVR in modern valve therapy.
- 7 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4049
Open AccessExploring Use-Rates of and Scientific Evidence on Sutureless Devices in Aortic Valve Replacement: A Bibliographic Meta-Analysis and Clinical Considerations
Sutureless aortic valve replacement (SuAVR) has emerged as a potential alternative to conventional surgical aortic valve replacement (SAVR), particularly in minimally invasive settings. However, its global adoption remains limited, with a notable concentration of use and scientific production in select European countries. This bibliographic meta-analysis systematically reviewed 538 studies to assess the evidence landscape surrounding SuAVR, highlighting a predominance of observational data, sparse randomized controlled trials (1.3%), and significant geographical imbalances in research output. Europe accounted for 80% of publications, while North America contributed less than 10%. Key structural factors—including reimbursement policies, earlier regulatory approvals, and population characteristics—appear to influence SuAVR adoption. Despite procedural advantages such as reduced cross-clamp times, concerns over cost, pacemaker implantation rates, and uncertain long-term durability persist. Importantly, SuAVR may offer its greatest clinical value by facilitating minimally invasive surgery, a niche still underutilized worldwide. The limited randomized data and industrial focus on transcatheter approaches have further hindered widespread acceptance. Our findings underscore the need for high-quality comparative trials and standardized guidelines to define the role of SuAVR in modern valve therapy.
- Open Access
- 3 May 2025
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 3 (4) , 829-833
What Happens After Declining Recommended Surgery? Analysis of Early-Stage Non-Small Cell Lung Cancer
- 3 May 2025
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 3 (4) , 829-833
Open AccessWhat Happens After Declining Recommended Surgery? Analysis of Early-Stage Non-Small Cell Lung Cancer